Records
Browse every document routed through Assort Design.
Route Filters
Study calls for new gold standard in research to treat non-alcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About F
One-line summary: The study advocates a new human-relevant gold standard using in vitro and omics techniques to better understand and treat non-alcoholic steatohepatitis (NASH), addressing limitations of current animal models.
Citations: 2 · Risk: 1 High / 1 Medium / 0 Low
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor January 9, 2026 PDF Version Agreement expands Madrigal’s pipeline and stre
One-line summary: Madrigal Pharmaceuticals expands its MASH pipeline through an exclusive global license for ervogastat, a Phase 2 oral DGAT-2 inhibitor, complementing its approved therapy Rezdiffra for innovative combination MASH treatments.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs February 11, 2026 PDF Version Company advances its leadership in MASH with an expande
One-line summary: Madrigal has expanded its MASH treatment pipeline by licensing six preclinical siRNA programs targeting genetic drivers of disease to complement its foundational therapy Rezdiffra.
Citations: 4 · Risk: 1 High / 0 Medium / 0 Low
Madrigal Pharmaceuticals outlined a cross-functional update in MASH lifecycle strategy centered on Rezdiffra (resmetirom). The company highlighted new pipeline partnerships and early-stage combination
One-line summary: Madrigal Pharmaceuticals is advancing Rezdiffra's MASH lifecycle strategy through novel partnerships and combination therapies to enhance fibrosis treatment and market positioning.
Citations: 4 · Risk: 0 High / 0 Medium / 0 Low
Madrigal Expands its MASH Pipeline with Exclusive Global Accessibility: Skip TopNav Consumer Products and Services News Automobiles and Parts News Food & Beverage News Home Goods & Construction News L
One-line summary: Madrigal Pharmaceuticals broadens its MASH treatment pipeline by securing exclusive global rights to six preclinical siRNA programs, complementing its foundational drug Rezdiffra and aiming for genetically targeted MASH therapies.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited July 30, 2025 PDF Version License agreement supports M
One-line summary: Madrigal Pharmaceuticals licenses orally-administered GLP-1 agonist SYH2086 to develop a best-in-class combination therapy with Rezdiffra for MASH treatment.
Citations: 5 · Risk: 1 High / 2 Medium / 0 Low